Congress clarifies: federal opioid grants can now fund test strips
H.R. 1562 — Test Strip Access Act of 2025 · Filed by Jasmine Crockett (D-TX) · 1 cosponsor · Introduced Feb 25, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill amends the 21st Century Cures Act to explicitly permit federal grants for opioid response programs to be used to distribute fentanyl and xylazine test strips to people who use drugs. Currently, the law allows grants for substance-use disorder prevention but does not expressly mention test strips; this amendment clarifies that test strips are an eligible use of those funds, removing ambiguity that may have discouraged their distribution.
Why we flagged it
The bill is a narrow, technical amendment that clarifies existing grant authority to include test strips—a standard harm-reduction tool. It does not create new funding or programs, only removes ambiguity in how existing opioid-response grants may be spent.
What the text implies
- Clarification may embolden state and tribal health departments to allocate existing grant funds to test-strip distribution without fear of federal audit or clawback, potentially shifting resources from other opioid interventions.
- Does not appropriate new money; effect depends on whether states and tribes choose to reallocate existing opioid-response grants toward test strips rather than treatment, medication, or other services.
Section numbers refer to the bill text the analysis read — linked under Primary records below.
Who it affects
Test strips allow people who use drugs to detect the presence of fentanyl and xylazine in their supply, enabling them to avoid or reduce overdose risk. Clarifying that federal grants can fund this distribution removes a legal barrier and expands access to a low-cost, evidence-based harm-reduction tool that saves lives.
Named in the bill
21st Century Cures Act, Section 1003(b)(4)(A), State and Tribal opioid-response programs, FDA (Federal Food, Drug, and Cosmetic Act)
Where it stands
1 cosponsor: 1 Republicans.
- Feb 25, 2025 — Introduced · Congress.gov: “Introduced in House”
- Feb 25, 2025 — Referred to House Committee on Energy and Commerce · Congress.gov: “Referred to the House Committee on Energy and Commerce”
Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.
How this was measured
Analysis — Quorum's AI read the bill text published by Congress.gov (394 characters) on Sep 21, 2026. Section numbers in the findings refer to that text, linked below; transparency and hidden-provision scores are compared against the median of 14,522 analysed bills.
Status and sponsors — Congress.gov's bill record — actions, committee referrals and cosponsors — loaded nightly. The timeline shows status changes, not every procedural action.
As of — page rendered 2026-09-21.
“Congress clarifies: federal opioid grants can now fund test strips” QuorumCivic. https://share.quorumcivic.app/bill/119/hr1562 Report an error